The main focus of my research is to improve targeted therapy for cancer, and to develop new rational strategies for combination of targeted agents. In the clinic, epidermal growth factor receptor (EGFR)-targeting antibodies or small kinase inhibitor molecules are widely used to treat patients with gastrointestinal (GI), breast, head and neck, and lung cancers. Unfortunately, the clinical efficacy of these agents is limited by intrinsic primary and acquired resistance factors.
- Analysis of pro-survival signaling networks and epithelial-to-mesenchymal transition, to predict effective therapeutic strategies
- New regulators of cisplatin resistance in head and neck cancers
- Constitutional defects in suppression of DNA double strand breaks (DSB) in familial colon cancer
Assistant Professor (h-index-15), Fox Chase Cancer Center– FCCC, USA
Attending Physician, Hematology / Medical Oncology, Fox Chase Cancer Center– FCCC, USA
- The main areas of my research are lung cancer, RNA-binding proteins (RBP), including Musashi-2, and their role in carcinogenesis.
- Study of signaling pathways that regulate RBP, mechanisms for the regulation of expression of proteins dependent on RBP, and modulation of targeted therapy with RBP.
- Transgenic model of knockout protein Musashi-2.